Colorectal Cancer

Colorectal Cancer Quality Measures

Cleveland Clinic is accredited by the National Accreditation Program for Rectal Cancer (NAPRC) which was developed through a collaboration between the OSTRiCh Consortium (Optimizing the Surgical Treatment of Rectal Cancer) and the Commission on Cancer (CoC), a quality program of the American College of Surgeons. The NAPRC's goal is to ensure patients with rectal cancer receive appropriate care using a multidisciplinary approach. NAPRC accreditation signifies demonstration of several rectal cancer care processes and quality metrics that have been proven to improve outcomes.

Quality: At Least 12 Lymph Nodes Removed and Examined Pathologically for Patients Undergoing Resection for Colon Cancer (N = 155)

2017

NCDC = National Cancer Database

ᵃThe National Cancer Database is a nationwide oncology outcomes database and is a joint program of the Commission on Cancer and the American Cancer Society.

Cleveland Clinic's performance was 97.4% (151 of 155 patients; 95% CI, 94.6%-99.9%) in 2017 for this National Cancer Databaseᵃ standard of care quality measure, exceeding the 85% standard performance rate.

Rate of Margin-Free Surgery for Colon and Rectal Cancer (N = 336)

2017

Cleveland Clinic's performance was 93.1% (313 of 336 patients; 95% CI, 90.4%-95.8%) in 2017 for the rate of margin-free surgery for colon and rectal cancer patient.

Percentage of Rectal Cancer Patients Presented at Tumor Boards N = 173)

2017

Cleveland Clinic's performance was 92% (159 of 173 patients; 95% CI, 88.0%-96.0%) in 2017 for rectal cancer patients presented at tumor boards.

Rate of Microsatellite Instability Screening in Colon and Rectal Cancer Patients¹ (N = 341)

2017

Microsatellite instability (MSI) is associated with colon and rectal cancer. Screening for MSI in patients can help to better determine the prognosis of their diagnosis and help identify potential cases of hereditary colorectal cancer syndromes.

¹Includes patients who had their surgery and microsatellite instability screening at Cleveland Clinic as a part of their initial course of treatment.

Cleveland Clinic's performance was 99.4% (339 of 341 patients; 95% CI, 97.9%-99.9%) in 2017 for patients that were screened for Microsatellite Instability.